Skip to content
About Us
Our Company
Our Team
Directors
Contact
Our Science
VAAST Platform
Mucosal Immunity
Platform Difference
Pipeline
COVID-19
Norovirus
Influenza
HPV
Publications
Investors
Careers
Vaxart Guiding Principles
Benefits
Open Positions
Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders
May 19, 2026
Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results
May 7, 2026
Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET
May 1, 2026
Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors
April 23, 2026
Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital
April 17, 2026
Vaxart Provides Business Update and Reports Full Year 2025 Financial Results
March 12, 2026
Vaxart to Host Upcoming Conference Calls
March 3, 2026
Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026
February 18, 2026
Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants
January 15, 2026
Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026
January 8, 2026
←
Previous Page
1
2
3
4
5
Next Page
→
